Obesity is a chronic, multifactorial disease associated with major cardiometabolic comorbidities and impaired quality of life. Dual GIP/GLP-1 receptor agonist pharmacotherapy has achieved substantially greater medically managed weight loss than previously available agents.

A Cochrane systematic review and meta-analysis of nine RCTs (7,111 participants) demonstrates that a dual GIP/GLP-1 receptor agonist administered weekly achieves approximately 16% body weight reduction versus placebo at 12–18 months (moderate-certainty evidence), sustained at 3.5 years, with no significant difference in major adverse cardiovascular events. The European Association for the Study of Obesity is developing a GRADE-based pharmacological framework evaluating approved obesity agents across individualized subgroups, including patients with type 2 diabetes, cardiovascular disease, sleep apnea, and metabolic liver disease, to provide clinically applicable, person-centered guidance.

Endocrinologists, obesity medicine specialists, cardiologists, and primary care physicians managing obesity will benefit from peer discussion of dual incretin pharmacotherapy evidence, individualized patient selection, combination with lifestyle modification, and long-term weight maintenance.

How do you incorporate dual GIP/GLP-1 receptor agonist therapy into your obesity management algorithm, and what patient-specific factors, including cardiovascular risk, diabetes status, or prior treatment response, guide agent selection? What are the most significant clinical challenges in sustaining long-term weight loss with pharmacological therapy for obesity, and how do you manage treatment discontinuation or weight regain?